Prof. Dr. med. Mario Schiffer

Lehrstuhl für Innere Medizin IV

DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE (2022) Pietschner R, Kolwelter J, Bosch A, Striepe K, Kannenkeril D, Ott C, Schiffer M, et al. Journal article ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE (2022) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Pietschner R, Striepe K, Schiffer M, Schmieder R Journal article IS BASAL NITRIC OXIDE ACTIVITY OF THE RENAL VASCULATURE ALTERED? ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL COMPARING TWO COMBINATION THERAPIES (2022) Kannenkeril D, Ott C, Bosch A, Striepe K, Pietschner R, Schiffer M, Schmieder R Journal article DETAILED ANALYSIS OF VASCULAR STIFFNESS IN PATIENTS WITH CHRONIC HEART FAILURE (2022) Pietschner R, Kolwelter J, Bosch A, Striepe K, Kannenkeril D, Ott C, Schiffer M, et al. Conference contribution ANGIOTENSIN PROFILES IN PATIENTS WITH HYPERTENSION AND TYPE 2 DIABETES WITH COMBINATION THERAPY OF EMPAGLIFLOZIN AND LINAGLIPTIN VERSUS METFORMIN AND INSULIN GLARGINE (2022) Bosch A, Poglitsch M, Kannenkeril D, Ott C, Pietschner R, Striepe K, Schiffer M, Schmieder R Conference contribution Peculiarities in the panoramic radiograph of patients with secondary hyperparathyroidism due to terminal renal disease: a radiologic controlled comparative study (2022) Möst T, Jahn AE, Heller KM, Schiffer M, Adler W, Rohde M, Weber M, et al. Journal article GENERATION OF PATIENT-SPECIFIC HIPSC-PODOCYTES TO STUDY PHENOTYPE-SPECIFIC ALTERATIONS AND TEST THERAPEUTIC TARGETS EX VIVO (2022) Rose V, Sopel N, Ohs A, Warnecke C, Schiffer M, Müller-Deile J Conference contribution The renal cancer risk allele at 14q24.2 activates a novel hypoxia-inducible transcription factor-binding enhancer of DPF3 expression (2022) Protze J, Naas S, Krüger R, Stöhr C, Kraus A, Grampp S, Schiffer M, et al. Journal article Renal denervation Really an alternative to reducing blood pressure? (2022) Striepe K, Schiffer M, Schmieder R Journal article The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial (2022) Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al. Journal article